TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00448721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine will be administered orally at 100mg PO daily with food.
Study: NCT01220336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants in primary care
Description: Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model \[Bodenheimer 2007\] for 12 months.
Study: NCT02277899

Intervention type: OTHER
Intervention: Communication regarding overweight status
Description: Pediatrician-patient/parent communication regarding child's high weight status

Intervention type: OTHER
Intervention: Risk-factor assessment and counseling
Description: Counseling regarding cardiovascular risk factor assessments/results.

Intervention type: OTHER
Intervention: Lifestyle behavior assessment and counseling
Description: Counseling regarding diet and lifestyle changes to improve weight status.

Intervention type: OTHER
Intervention: Interval follow-up to readdress weight
Description: Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.

Intervention type: OTHER
Intervention: Patient-centered communication
Description: Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
Study: NCT01025817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and tacrolimus
Description: Everolimus:~* Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~* Dose: 1.5 mg per day~* Frequency: 0.75 mg twice daily~Tacrolimus:~* Dose adjusted to maintain specific blood levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil and tacrolimus
Description: Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
Study: NCT01165151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral weight loss program
Description: weekly, group-based lifestyle weight loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral weight loss program
Description: weekly, group-based lifestyle weight loss program
Study: NCT02268006

Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT-SIB

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Study: NCT04182256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS
Description: Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
Study: NCT00230100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Women's Recovery Group
Description: The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mixed-gender Group Drug Counseling
Description: Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
Study: NCT04449224

Intervention type: DRUG
Intervention: Adalimuab, Etanercept, Tocilizumab, or Abatacept
Description: A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.

Intervention type: DRUG
Intervention: Tofacitinib or Baricitinib
Description: A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
Study: NCT01800435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aPCC, aPCC + TXA
Description: Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aPCC, aPCC + TXA
Description: Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa, rFVIIa + TXA
Description: NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa, rFVIIa + TXA
Description: NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
Study: NCT03527784

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietene Macro
Description: Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex Parastomal
Description: Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamesh IPST
Description: Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
Study: NCT04843280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FORCE therapeutics (physical therapy)
Description: 6 weeks of internet based physical therapy following arthroscopic knee surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Outpatient Physical Therapy
Description: 6 weeks of outpatient physical therapy following arthroscopic knee surgery
Study: NCT00399529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic GM-CSF-secreting breast cancer vaccine
Description: the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
Study: NCT03435380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation
Description: Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient activation
Description: Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary care physician activation
Description: Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Mailed educational materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Mailed educational materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Mailed educational materials.
Study: NCT00115934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blalock-Taussig pulmonary artery shunt
Description: Performed at stage I palliative surgery for babies born with HLHS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular to pulmonary artery shunt
Description: Performed at stage I palliative surgery for babies born with HLHS
Study: NCT04009889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: capsule containing a probiotic blend of 5 different Lactobacilli
Description: n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
Description: n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
Study: NCT01021267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saw palmetto berry extract
Description: 1x daily 1 capsule containing 320mg lipophilic extract
Study: NCT02862119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFR Treatment Arm
Description: Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment Arm
Description: Initial Conservative management of non-culprit lesions during index hospital admission
Study: NCT01394159

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 22G ProCore biopsy needle
Description: Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 22G standard FNA needle
Description: Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
Study: NCT02073474

Intervention type: DRUG
Intervention: Sativex®
Description: Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Study: NCT03178409

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Removal of a part of the liver

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Removal of a part of the liver

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Removal of a part of the liver
Study: NCT00988637

Intervention type: DRUG
Group type: OTHER
Intervention: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen
Description: Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: Clobex® Spray morning and Vectical™ Ointment evening regimen
Description: Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
Study: NCT03462589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Study: NCT02354885

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tranexamic Acid
Description: Coagulation Management / Efficiency
Study: NCT04614636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Monoclonal Antibody, CD38, Anti-CD38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Monoclonal Antibody
Study: NCT01531075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENGERIX-B (HBV Vaccine)
Description: ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac
Description: Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
Study: NCT00592813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Strong for Life
Description: The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cardiovascular nutrition education
Description: administered as an attention control intervention using home visits, phone calls and mail-outs of information
Study: NCT00933881

Intervention type: OTHER
Intervention: Determining a change in heart rate variability post delivery of the baby
Description: Determining a change in heart rate variability post delivery of the baby
Study: NCT01057927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 capsules 2x100mg BID for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
Study: NCT01077817

Intervention type: DRUG
Intervention: Alendronate

Intervention type: DRUG
Intervention: Alendronate

Intervention type: DRUG
Intervention: Alendronate

Intervention type: DRUG
Intervention: Etidronate
Study: NCT01598636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral tibial tunnel
Description: To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
Study: NCT01269853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle
Study: NCT04016870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reconditioned Pacemaker
Description: Devices from the three manufacturers below will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Pacemaker
Description: Devices from the four manufacturers below will be used.
Study: NCT00855686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20mg once daily oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose
Study: NCT00848627

Intervention type: OTHER
Intervention: Specimen and questionnaires only
Description: Specimen and questionnaires only
Study: NCT01622413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: joimax TESSYS
Description: Transforaminal Endoscopic Surgery System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Standard procedure for disc surgery
Study: NCT02867566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI301 plus CHOP
Description: Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab plus CHOP
Description: Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.